vs
TPG Mortgage Investment Trust, Inc.（MITT）与SUTRO BIOPHARMA, INC.（STRO）财务数据对比。点击上方公司名可切换其他公司
TPG Mortgage Investment Trust, Inc.的季度营收约是SUTRO BIOPHARMA, INC.的1.8倍（$20.4M vs $11.6M），TPG Mortgage Investment Trust, Inc.同比增速更快（17.7% vs -21.4%），过去两年TPG Mortgage Investment Trust, Inc.的营收复合增速更高（9.1% vs -5.4%）
TPG抵押贷款投资信托是由全球另类资产管理公司TPG管理的房地产投资信托，主要投资于美国市场的住宅及商业抵押贷款支持证券、履约及不良抵押贷款、其他信用关联地产资产，通过持有资产的净利息收入和资产处置收益实现回报。
Sutro Biopharma是一家上市生物科技公司，总部位于加州南旧金山，专注于临床阶段药物的研发、开发与生产。公司依托自主专有的无细胞蛋白质合成平台，结合蛋白质工程与理性设计技术开发肿瘤治疗药物。公司2003年成立时名为Fundamental Applied Biology，2009年改用现名。
MITT vs STRO — 直观对比
营收规模更大
MITT
是对方的1.8倍
$11.6M
营收增速更快
MITT
高出39.0%
-21.4%
两年增速更快
MITT
近两年复合增速
-5.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.4M | $11.6M |
| 净利润 | $13.3M | — |
| 毛利率 | — | — |
| 营业利润率 | 67.1% | — |
| 净利率 | 65.0% | — |
| 营收同比 | 17.7% | -21.4% |
| 净利润同比 | -7.0% | 35.4% |
| 每股收益（稀释后） | $0.27 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MITTSTRO
| Q4 25 | $20.4M | $11.6M | ||
| Q3 25 | $19.5M | $9.7M | ||
| Q2 25 | $17.8M | $63.7M | ||
| Q1 25 | $18.8M | $17.4M | ||
| Q4 24 | $17.4M | $14.8M | ||
| Q3 24 | $14.9M | $8.5M | ||
| Q2 24 | $16.4M | $25.7M | ||
| Q1 24 | $17.2M | $13.0M |
净利润MITTSTRO
| Q4 25 | $13.3M | — | ||
| Q3 25 | $20.0M | $-56.9M | ||
| Q2 25 | $3.9M | $-11.5M | ||
| Q1 25 | $11.5M | $-76.0M | ||
| Q4 24 | $14.3M | $-72.4M | ||
| Q3 24 | $16.6M | $-48.8M | ||
| Q2 24 | $3.9M | $-48.0M | ||
| Q1 24 | $20.9M | $-58.2M |
营业利润率MITTSTRO
| Q4 25 | 67.1% | — | ||
| Q3 25 | — | -499.9% | ||
| Q2 25 | 20.9% | -5.2% | ||
| Q1 25 | 54.6% | -393.8% | ||
| Q4 24 | 76.7% | -440.7% | ||
| Q3 24 | — | -797.2% | ||
| Q2 24 | 18.4% | -189.4% | ||
| Q1 24 | — | -435.0% |
净利率MITTSTRO
| Q4 25 | 65.0% | — | ||
| Q3 25 | 102.5% | -586.6% | ||
| Q2 25 | 22.2% | -18.0% | ||
| Q1 25 | 60.9% | -436.6% | ||
| Q4 24 | 82.2% | -489.2% | ||
| Q3 24 | 111.3% | -572.6% | ||
| Q2 24 | 24.0% | -186.8% | ||
| Q1 24 | 121.6% | -447.5% |
每股收益（稀释后）MITTSTRO
| Q4 25 | $0.27 | — | ||
| Q3 25 | $0.47 | $-0.67 | ||
| Q2 25 | $-0.05 | $-0.14 | ||
| Q1 25 | $0.21 | $-0.91 | ||
| Q4 24 | $0.30 | $-27.63 | ||
| Q3 24 | $0.40 | $-0.59 | ||
| Q2 24 | $-0.02 | $-0.59 | ||
| Q1 24 | $0.55 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.8M | $141.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $560.7M | $-132.5M |
| 总资产 | $8.7B | $173.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MITTSTRO
| Q4 25 | $57.8M | $141.4M | ||
| Q3 25 | $59.0M | $167.6M | ||
| Q2 25 | $88.7M | $205.1M | ||
| Q1 25 | $115.5M | $249.0M | ||
| Q4 24 | $118.7M | $316.9M | ||
| Q3 24 | $102.5M | $388.3M | ||
| Q2 24 | $120.9M | $375.6M | ||
| Q1 24 | $100.3M | $267.6M |
股东权益MITTSTRO
| Q4 25 | $560.7M | $-132.5M | ||
| Q3 25 | $559.8M | $-87.3M | ||
| Q2 25 | $536.4M | $-32.1M | ||
| Q1 25 | $543.9M | $-25.8M | ||
| Q4 24 | $543.4M | $44.6M | ||
| Q3 24 | $540.1M | $111.2M | ||
| Q2 24 | $533.5M | $152.2M | ||
| Q1 24 | $539.6M | $98.0M |
总资产MITTSTRO
| Q4 25 | $8.7B | $173.8M | ||
| Q3 25 | $9.0B | $209.7M | ||
| Q2 25 | $7.5B | $262.4M | ||
| Q1 25 | $7.3B | $321.4M | ||
| Q4 24 | $6.9B | $387.2M | ||
| Q3 24 | $7.0B | $451.8M | ||
| Q2 24 | $7.1B | $489.0M | ||
| Q1 24 | $6.4B | $403.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.6M | $-177.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 4.48× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MITTSTRO
| Q4 25 | $59.6M | $-177.2M | ||
| Q3 25 | $17.4M | $-38.2M | ||
| Q2 25 | $11.5M | $-44.7M | ||
| Q1 25 | $12.0M | $-67.9M | ||
| Q4 24 | $55.8M | $-71.7M | ||
| Q3 24 | $14.5M | $-64.5M | ||
| Q2 24 | $13.7M | $9.5M | ||
| Q1 24 | $12.0M | $-64.7M |
现金转化率MITTSTRO
| Q4 25 | 4.48× | — | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 2.92× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 3.91× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 3.50× | — | ||
| Q1 24 | 0.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
